338 related articles for article (PubMed ID: 19304304)
1. Restriction of HIV-1 by APOBEC3G is cytidine deaminase-dependent.
Browne EP; Allers C; Landau NR
Virology; 2009 May; 387(2):313-21. PubMed ID: 19304304
[TBL] [Abstract][Full Text] [Related]
2. [Advances in the study of molecular mechanism of APOBEC3G anti-HIV-1].
Fan B; Cen S; Jiang JD
Yao Xue Xue Bao; 2008 Jul; 43(7):678-82. PubMed ID: 18819469
[TBL] [Abstract][Full Text] [Related]
3. Heat shock protein 70 inhibits HIV-1 Vif-mediated ubiquitination and degradation of APOBEC3G.
Sugiyama R; Nishitsuji H; Furukawa A; Katahira M; Habu Y; Takeuchi H; Ryo A; Takaku H
J Biol Chem; 2011 Mar; 286(12):10051-7. PubMed ID: 21228271
[TBL] [Abstract][Full Text] [Related]
4. The DNA deaminase activity of human APOBEC3G is required for Ty1, MusD, and human immunodeficiency virus type 1 restriction.
Schumacher AJ; Haché G; Macduff DA; Brown WL; Harris RS
J Virol; 2008 Mar; 82(6):2652-60. PubMed ID: 18184715
[TBL] [Abstract][Full Text] [Related]
5. Mechanism of Enhanced HIV Restriction by Virion Coencapsidated Cytidine Deaminases APOBEC3F and APOBEC3G.
Ara A; Love RP; Follack TB; Ahmed KA; Adolph MB; Chelico L
J Virol; 2017 Feb; 91(3):. PubMed ID: 27881650
[TBL] [Abstract][Full Text] [Related]
6. HIV-1 viral infectivity factor (Vif) alters processive single-stranded DNA scanning of the retroviral restriction factor APOBEC3G.
Feng Y; Love RP; Chelico L
J Biol Chem; 2013 Mar; 288(9):6083-94. PubMed ID: 23316055
[TBL] [Abstract][Full Text] [Related]
7. [Recent advances in the study of mechanism of APOBEC3G against virus].
Zhu YP; Jiang JD; Peng ZG
Yao Xue Xue Bao; 2014 Jan; 49(1):30-6. PubMed ID: 24783502
[TBL] [Abstract][Full Text] [Related]
8. APOBEC3F can inhibit the accumulation of HIV-1 reverse transcription products in the absence of hypermutation. Comparisons with APOBEC3G.
Holmes RK; Koning FA; Bishop KN; Malim MH
J Biol Chem; 2007 Jan; 282(4):2587-95. PubMed ID: 17121840
[TBL] [Abstract][Full Text] [Related]
9. Identification of a novel HIV-1 inhibitor targeting Vif-dependent degradation of human APOBEC3G protein.
Pery E; Sheehy A; Nebane NM; Brazier AJ; Misra V; Rajendran KS; Buhrlage SJ; Mankowski MK; Rasmussen L; White EL; Ptak RG; Gabuzda D
J Biol Chem; 2015 Apr; 290(16):10504-17. PubMed ID: 25724652
[TBL] [Abstract][Full Text] [Related]
10. Human apolipoprotein B mRNA-editing enzyme-catalytic polypeptide-like 3G (APOBEC3G) is incorporated into HIV-1 virions through interactions with viral and nonviral RNAs.
Svarovskaia ES; Xu H; Mbisa JL; Barr R; Gorelick RJ; Ono A; Freed EO; Hu WS; Pathak VK
J Biol Chem; 2004 Aug; 279(34):35822-8. PubMed ID: 15210704
[TBL] [Abstract][Full Text] [Related]
11. Evolution of HIV-1 isolates that use a novel Vif-independent mechanism to resist restriction by human APOBEC3G.
Haché G; Shindo K; Albin JS; Harris RS
Curr Biol; 2008 Jun; 18(11):819-24. PubMed ID: 18501607
[TBL] [Abstract][Full Text] [Related]
12. APOBEC3G and APOBEC3F Act in Concert To Extinguish HIV-1 Replication.
Krisko JF; Begum N; Baker CE; Foster JL; Garcia JV
J Virol; 2016 May; 90(9):4681-4695. PubMed ID: 26912618
[TBL] [Abstract][Full Text] [Related]
13. Regulation of Vif mRNA splicing by human immunodeficiency virus type 1 requires 5' splice site D2 and an exonic splicing enhancer to counteract cellular restriction factor APOBEC3G.
Mandal D; Exline CM; Feng Z; Stoltzfus CM
J Virol; 2009 Jun; 83(12):6067-78. PubMed ID: 19357165
[TBL] [Abstract][Full Text] [Related]
14. Endogenous origins of HIV-1 G-to-A hypermutation and restriction in the nonpermissive T cell line CEM2n.
Refsland EW; Hultquist JF; Harris RS
PLoS Pathog; 2012; 8(7):e1002800. PubMed ID: 22807680
[TBL] [Abstract][Full Text] [Related]
15. Induction of heat-shock protein 70 by prostaglandin A₁ inhibits HIV-1 Vif-mediated degradation of APOBEC3G.
Sugiyama R; Abe M; Nishitsuji H; Murakami Y; Takeuchi H; Takaku H
Antiviral Res; 2013 Sep; 99(3):307-11. PubMed ID: 23831493
[TBL] [Abstract][Full Text] [Related]
16. APOBEC3G-UBA2 fusion as a potential strategy for stable expression of APOBEC3G and inhibition of HIV-1 replication.
Li L; Liang D; Li JY; Zhao RY
Retrovirology; 2008 Aug; 5():72. PubMed ID: 18680593
[TBL] [Abstract][Full Text] [Related]
17. APOBEC3G complexes decrease human immunodeficiency virus type 1 production.
Martin KL; Johnson M; D'Aquila RT
J Virol; 2011 Sep; 85(18):9314-26. PubMed ID: 21752914
[TBL] [Abstract][Full Text] [Related]
18. Differential sensitivity of "old" versus "new" APOBEC3G to human immunodeficiency virus type 1 vif.
Goila-Gaur R; Khan MA; Miyagi E; Strebel K
J Virol; 2009 Jan; 83(2):1156-60. PubMed ID: 19004939
[TBL] [Abstract][Full Text] [Related]
19. Anti-APOBEC3G activity of HIV-1 Vif protein is attenuated in elite controllers.
Kikuchi T; Iwabu Y; Tada T; Kawana-Tachikawa A; Koga M; Hosoya N; Nomura S; Brumme ZL; Jessen H; Pereyra F; Trocha A; Walker BD; Iwamoto A; Tokunaga K; Miura T
J Virol; 2015 May; 89(9):4992-5001. PubMed ID: 25717111
[TBL] [Abstract][Full Text] [Related]
20. HIV-1 Vif can directly inhibit apolipoprotein B mRNA-editing enzyme catalytic polypeptide-like 3G-mediated cytidine deamination by using a single amino acid interaction and without protein degradation.
Santa-Marta M; da Silva FA; Fonseca AM; Goncalves J
J Biol Chem; 2005 Mar; 280(10):8765-75. PubMed ID: 15611076
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
